Biotech entity
All 2 tracked stories fall under one category: pharma. Apogee Therapeutics is most often covered alongside AbbVie, which appears in 1 of these 2 stories. They are less corroborated than the beat average, carrying 2 original sources each against 4.1 for the same window.
Last mentioned: Jul 28, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: pharma. Apogee Therapeutics is most often covered alongside AbbVie, which appears in 1 of these 2 stories. They are less corroborated than the beat average, carrying 2 original sources each against 4.1 for the same window. The 132-day window averages about 0.1 stories each week. Their average consequence score of 5 runs below the beat's 6.5 for that window. This profile follows 2 Biotech stories mentioning Apogee Therapeutics across the period from March 19, 2026 to July 28, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 276 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Apogee Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
AbbVie's second-quarter results, expected to show $3.61 EPS, hinge on the continued clinical and commercial success of Rinvoq and Skyrizi. The Apogee deal underscores a deepening immunology pipeline as Humira fades into the rearview.
Source: The Motley Fool · Thomas Niel (us)
Apogee Therapeutics and Arcturus Therapeutics experienced a wave of conflicting analyst activity on Thursday, with both companies facing significant downgrades alongside new initiations. This institutional tug-of-war highlights the increasing volatility and selective nature of investment in mid-cap biotechnology firms.
Apogee Therapeutics is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
